Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET/CT Imaging With 124I-Evuzamitide in Lumbar Spinal Stenosis or Carpal Tunnel Syndrome
NCT06907849Phase 2Enrolling by invitation
- Sponsor
- University of Tennessee Graduate School of Medicine
- Start
- May 2025
- Primary completion
- Mar 2027
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 124I-evuzamitide in cardiac amyloidosis and amyloidosis, sponsored by University of Tennessee Graduate School of Medicine. Primary endpoint: Detection of cardiac amyloidosis using 124I-evuzamitide PET/CT imaging at 8 days. Started May 2025; status: enrolling by invitation.
02
Drugs
124I-evuzamitide
03
Conditions
cardiac amyloidosisamyloidosis
Beyond the preview
Go deeper on NCT06907849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06907849.